Your browser doesn't support javascript.
loading
Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment and Prevention for People Experiencing Homelessness.
Mehtani, Nicky J; Strough, Alix; Strieff, Sarah; Zevin, Barry; Eveland, Joanna; Riley, Elise D; Gandhi, Monica.
Afiliación
  • Mehtani NJ; Department of Psychiatry & Behavioral Sciences, University of California, San Francisco, CA.
  • Strough A; Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, CA; and.
  • Strieff S; Division of HIV, ID & Global Medicine, Department of Medicine, University of California, San Francisco, CA.
  • Zevin B; Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, CA; and.
  • Eveland J; Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, CA; and.
  • Riley ED; Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, CA; and.
  • Gandhi M; Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, CA; and.
J Acquir Immune Defic Syndr ; 96(1): 61-67, 2024 05 01.
Article en En | MEDLINE | ID: mdl-38346426
ABSTRACT

BACKGROUND:

Long-acting (LA) antiretrovirals may provide meaningful benefit to people who use drugs and people experiencing homelessness (PEH) who face disproportionate structural and psychosocial barriers in adhering to daily oral HIV antiretroviral therapy or pre-exposure prophylaxis (PrEP), but their use in these populations has not been studied.

SETTING:

The Maria X. Martinez Health Resource Center is a low-barrier (eg, no appointment) community-based clinic serving San Francisco PEH.

METHODS:

A multidisciplinary care model with robust monitoring and outreach support was developed to provide LA antiretroviral therapy (ART) and LA-PrEP to eligible patients experiencing difficulties adhering to oral antiretrovirals. Feasibility was assessed by evaluating the rates of HIV viremia and on-time injections among patients receiving LA antiretrovirals over the first 24 months of program implementation.

RESULTS:

Between November 2021 and November 2023, 33 patients initiated LA-ART or LA-PrEP (median age, 37 years; 27% transgender/nonbinary; 73% non-White; 27% street homeless; 52% sheltered homeless; 30% with opioid use disorder; 82% with methamphetamine use disorder). Among 18 patients with HIV, 14 initiated LA-ART injections with detectable viremia (median CD4 count, 340 cells/mm 3 ; mean log 10 viral load, 3.53; SD, 1.62), 8 had never previously been virally suppressed, and all but 1 achieved or maintained virologic suppression (mean, 9.67 months; SD, 8.30). Among 15 LA-PrEP patients, all remained HIV negative (mean, 4.73 months; SD, 2.89). Of 224 total injections administered, 8% were delayed >7 days.

DISCUSSION:

The implementation of LA antiretrovirals is feasible in low-barrier, highly supportive clinical settings serving vulnerable PEH. Expansion of such programs will be critical in ending the HIV epidemic.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Personas con Mala Vivienda / Infecciones por VIH / Fármacos Anti-VIH / Profilaxis Pre-Exposición Aspecto: Determinantes_sociais_saude / Implementation_research Límite: Adult / Humans Idioma: En Revista: J Acquir Immune Defic Syndr Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Personas con Mala Vivienda / Infecciones por VIH / Fármacos Anti-VIH / Profilaxis Pre-Exposición Aspecto: Determinantes_sociais_saude / Implementation_research Límite: Adult / Humans Idioma: En Revista: J Acquir Immune Defic Syndr Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos